Testing version — LOERadar is in active testing. Features and data may change.

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE (AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN) | LOERadar

Viewing data from:

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

ANDA

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN | A201593 | TORRENT PHARMACEUTICALS LTD

5 strengths0 unique patents0 unique exclusivities

Approval Letters

2 letters from Drugs@FDA

Date	Submission	Document
Jun 10, 2015	ORIG -1	View Letter (PDF)
Nov 4, 2014	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (5)

Sort:

#001 — EQ 5MG BASE;12.5MG;160MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jun 3, 2015

No patent or exclusivity listings for this strength.

#002 — EQ 5MG BASE;25MG;160MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jun 3, 2015

#003 — EQ 10MG BASE;12.5MG;160MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jun 3, 2015

#004 — EQ 10MG BASE;25MG;160MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jun 3, 2015

#005 — EQ 10MG BASE;25MG;320MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Jun 3, 2015